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Abstract
Introduction: CREST (calcinosis, Raynaud phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasia)
syndrome comprising calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly and telangiectasia
and primary sclerosing cholangitis are both chronic fibrotic diseases but the association between them is extremely rare.
While primary sclerosing cholangitis has been associated with diffuse cutaneous scleroderma, the association
with limited cutaneous scleroderma or CREST has not been previously reported in the literature. This case report
illustrates the association between CREST and primary sclerosing cholangitis.
Case presentation: We report the case of an 84-year-old Asian woman with a long history of CREST who was
admitted with abdominal pain, fatigue and progressive derangement of her liver enzymes. This was initially
thought to be secondary to her bosentan therapy for pulmonary hypertension but it persisted despite bosentan being
ceased. Primary sclerosing cholangitis was subsequently diagnosed on magnetic resonance cholangiopancreatography
and she was referred to a hepatologist for treatment.
Conclusions: This case highlights the need to consider primary sclerosing cholangitis in patients with CREST who
present with abdominal symptoms and deranged liver enzymes when other causes have been excluded. Relevant
differential diagnoses for this presentation, which can be difficult to exclude, include immunoglobulin G4-associated
cholangitis and antimitochondrial antibody negative primary biliary cirrhosis. It is of particular significance to
rheumatologists and gastroenterologists but has broader relevance to all medical specialists involved in the
care of patients with CREST.
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Introduction
Primary sclerosing cholangitis (PSC) is a rare idiopathic
chronic progressive liver disease resulting in fibro-
obliterative inflammation of the hepatic bile ducts and
ultimately cirrhosis and liver failure [1]. It is more fre-
quent in men and strongly associated with inflammatory
bowel disease [1, 2]. The liver disease usually associated
with scleroderma is primary biliary cirrhosis (PBC) with
approximately 15 % of patients with PBC reported to
have scleroderma [3]. The association was first made by
Murray-Lyon et al. in the 1970s [4]. In contrast, the re-
lationship between PSC and scleroderma is extremely
rare [3] with only one case report, to the best of our
knowledge, of PSC and diffuse cutaneous scleroderma [2].
We describe a case of PSC occurring in a patient with
CREST (calcinosis cutis, Raynaud phenomenon, esophageal
dysmotility, sclerodactyly and telangiectasia) syndrome,
which is a type of limited cutaneous scleroderma.* Correspondence: alice.c.powell@gmail.com
1The Queen Elizabeth Hospital, Adelaide, SA, Australia
Full list of author information is available at the end of the article
JOURNAL OF MEDICAL
CASE REPORTS
© 2015 Powell and McNeil. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Powell and McNeil Journal of Medical Case Reports
DOI 10.1186/s13256-015-0747-9
Case presentation
An 84-year-old Asian woman was electively admitted to
our hospital for investigation of a 6-month history of liver
function test (LFT) derangement, abdominal pain, fatigue
and weight loss. The results of her LFTs were as follows:
alkaline phosphatase 953 U/L, gamma glutamyl transpep-
tidase 1164 U/L, alanine aminotransferase 81 U/L, aspar-
tate aminotransferase 89 U/L, bilirubin 13 μmol/L and
albumin 33 g/L. She had experienced Raynaud’s
phenomenon for 50 years and had a confirmed diagnosis
of CREST complicated by pulmonary hypertension, for
which she had been treated with bosentan for the past 7
years. Her abdominal pain was initially attributed to
esophageal dysmotility associated with her CREST and
had improved with pantoprazole.
The most frequent severe side effect of bosentan is liver
toxicity, typically manifested by a transaminasemia [5]. Of
interest, animal models have demonstrated that bosentan
may also cause cholestatic liver injury through inhibition
of the bile salt export pump (BSEP) [6]. Our patient’s LFT
derangement was initially attributed to bosentan and this
was decreased and then changed to macitentan which
does not interfere with BSEP [6]. However, her LFT
derangement gradually worsened despite these measures
and therefore other causes were sought. There were no
other new medications, her hepatitis serology was negative
and there was no evidence of cholecystitis, cholelithiasis
or biliary obstruction on ultrasound. Computed tomog-
raphy (CT) of her abdomen was also unremarkable. An
autoimmune screen revealed positive antinuclear antibody
consistent with CREST, antimitochondrial antibody and
other liver autoantibodies negative. Immunoglobulin levels
including immunoglobulin G4 (IgG4) were normal.
Tumor markers including cancer antigen 19–9 (CA 19–9)
and carcinoembryonic antigen (CEA) were similarly nor-
mal. She proceeded to magnetic resonance cholangiopan-
creatography (MRCP) which demonstrated a prominent
common bile duct and prominent irregular central hepatic
ducts with areas of beading and narrowing in both lobes
favoring stricturing and PSC (Fig. 1).
A liver biopsy was not pursued given her age and co-
morbidities, in particular her pulmonary hypertension.
While this may have provided useful additional informa-
tion particularly in the exclusion of other differential
diagnoses, findings can be nonspecific [7]. In addition, a
biopsy is generally not required for the diagnosis of PSC
where cholestatic biochemical abnormalities and charac-
teristic changes on cholangiography are present.
Discussion
PSC is a complex heterogeneous probably immune-
mediated disease with an unpredictable clinical presenta-
tion and course. Diagnosis is made in patients with a
cholestatic biochemical profile and characteristic bile
duct changes on cholangiography (MRCP or endoscopic
retrograde cholangiopancreatography, ERCP) where sec-
ondary causes of sclerosing cholangitis have been ex-
cluded [1]. Typical symptoms include right upper
quadrant abdominal pain, fatigue, pruritus and weight
loss. Autoantibodies have no role in the routine diagno-
sis of PSC but antimitochondrial antibody is usually
negative whereas it is positive in PBC [1]. Abdominal
ultrasound and CT findings are usually nonspecific and
ERCP has been regarded as the gold standard for diag-
nosis. However, MRCP has comparable diagnostic accur-
acy and is noninvasive without the potential for
pancreatitis and bacterial cholangitis [1]. In a meta-
analysis of six studies, the sensitivity and specificity of
MRCP for diagnosing PSC were 86 and 94 % respect-
ively [8]. In the presence of an abnormal cholangiogram,
a liver biopsy is not required to establish a diagnosis of
PSC. No drug therapy has been conclusively proven to
alter the natural history of this disorder and liver trans-
plantation is the treatment of choice for advanced liver
disease [1].
PSC should be differentiated from secondary causes of
sclerosing cholangitis and IgG4-associated cholangitis.
Another potential differential diagnosis for this case was
antimitochondrial antibody negative PBC as antimito-
chondrial antibody may be negative in less than 10 % of
cases [9]. However, patients with PBC should have a
normal biliary tree on cholangiography [9]. Secondary
causes of PSC were ruled out on the basis of our
patient’s history, physical examination and imaging
studies. Of importance, there was no dominant stricture
on MRCP. IgG4-associated cholangitis is more difficult
Fig. 1 Magnetic resonance cholangiopancreatography demonstrating
prominent common bile duct and prominent irregular hepatic ducts
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to differentiate and it is possible that IgG4-associated
cholangitis, autoimmune pancreatitis and PSC are differ-
ent manifestations of the same disease [10]. This is,
however, an important distinction as IgG4-associated
cholangitis may be glucocorticoid responsive [10], while
no effective medical therapy is available for PSC. This
diagnosis was thought less likely in our patient’s case as
IgG4-associated cholangitis rarely occurs in the absence
of pancreatitis, for which there was no evidence, and her
IgG4 level was normal [10].
Conclusions
Both scleroderma and PSC are fibrotic diseases with
widespread connective tissue disturbance occurring in
CREST and abnormal collagen deposition in the bile
duct epithelium. While PSC has been reported to occur
in diffuse cutaneous systemic sclerosis, this is the first
case report of PSC occurring with limited cutaneous
systemic sclerosis.
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